<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784236</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY TC MENARINI</org_study_id>
    <nct_id>NCT02784236</nct_id>
  </id_info>
  <brief_title>INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.</brief_title>
  <official_title>INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study of 6 months of evolution in people with type 1 diabetes with insulin
      multidose (MDI) and HbA1c&gt; 7%. Patients were evaluated clinical, metabolic and psychological
      baseline and at 6 months, with a telematic visit at 3 months. We analyzed: glycemic control
      (HbA1c), glycemic variability (SD and MAGE), depressive symptoms (BDI-II), anxiety (STAI),
      treatment-related (DDS) distress, fear of hypoglycemia (FH-15), adhesion treatment (SCI-R),
      quality of life (DQOL) and treatment satisfaction (DTSQ) and the platform.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To analyze the metabolic impact measured through HbA1c of a telemedicine program by MenaDiab® online platform in the care of patients with DM1.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Metabolic Impact</condition>
  <arm_group>
    <arm_group_label>pre-post evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients undergo the condition of telemedicine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>telemedicine</intervention_name>
    <description>The study population corresponds to patients&gt; 18 and &lt;65 years with DM1 of&gt; 1 year of evolution, and treated with MDI HbA1c&gt; 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele</description>
    <arm_group_label>pre-post evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with DM1 plus 1 year of evolution.

          -  Age ≥18 and &lt;65 years.

          -  HbA1c prior to study inclusion&gt; 7%.

          -  MDI intensive insulin therapy in basal-bolus regimen.

          -  Patients candidates for telemonitoring. Approximately 50% of the patients should work
             with phone or tablet with Android operating system with active data rate to use
             wireless solution (bluetooth) OnLine MenaDiab® telemedicine. The remaining patients
             will work with the USB cable solution telemedicine MenaDiab® OnLine.

          -  Patients who have given written informed consent.

        Exclusion Criteria:

          -  Treatment with ISCI.

          -  Chronic kidney disease, liver disease, thyroid dysfunction (hypothyroidism except
             properly treated and controlled).

          -  Pregnant or planning pregnancy.

          -  Diabetes mellitus type 2.

          -  Severe psychological disorders.

          -  Lack of cooperation (informed consent).

          -  Patients who are participating in other clinical studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARIA SOLEDAD RUIZ DE ADANA, MD phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FIMABIS</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

